Ultra-fast imaging — quantitative precision,
powerful MRI AI agent
Ultra-fast imaging
quantitative precision
powerful MRI AI agent
An AI agent that raises
MRI efficiency and diagnostic accuracy together
NeuroOMx is deployed on MediOMx, PMX's medical data AI platform,
shortening long MRI scan times while enabling quantitative precision diagnosis
and transforming image-based diagnosis through AI summary reports.
An AI agent that raises
MRI efficiency and diagnostic accuracy together
NeuroOMx is deployed on MediOMx,
PMX's medical data AI platform,
shortening long MRI scan times while enabling quantitative precision diagnosis
and transforming image-based diagnosis through AI summary reports.
40-minute MRI scans in 15 minutes
Greater clinical efficiency
Long MRI scans —
15 minutes is enough
Automated imaging protocols reduce MRI scan time from 40 minutes to 15 —
a 62.5% time savings.
This increases hospital throughput so more patients can be seen,
and faster diagnosis in emergencies helps secure the golden hour.
40-minute MRI scans
in 15 minutes
Greater clinical efficiency
Long MRI scans — 15 minutes is enough
Automated imaging protocols reduce MRI scan time from 40 minutes to 15 —
a 62.5% time savings. Increased hospital throughput means
more patients can be seen, and faster diagnosis in emergencies
helps secure the golden hour.
Precisely measure brain structure,
quantify it, and capture
subtle signals of degenerative disease
AI-based image enhancement improves MRI data quality
and precisely quantifies brain structure volumes
As SaMD that analyzes brain anatomy
and comprehensively evaluates neurological function,
it supports early detection and precise diagnosis of degenerative brain disease.
Precisely measure brain structure,
quantify it, and capture
subtle signals of degenerative disease
AI image enhancement improves data quality, precisely analyzes and quantifies brain structure,
and as SaMD that comprehensively evaluates neurological function,
supports early detection and precise diagnosis
of degenerative brain disease
Precision diagnosis
powered by AI MRI auto-quantification
LOW data
3D measurement
AI analyzes MRI LOW data
and reconstructs it into high-quality, precise 3D
medical data through deep learning algorithms
Density-Texture Analysis
Analyzes tissue density and surface texture
characteristics to
quantify specificity
Volumetric Quantification
Automatically calculates region volume
and through comparative analysis
delivers meaningful quantitative results
Automated Segmentation
Automatically recognizes structures,
precisely segments brain subregions,
and clearly delineates anatomical structures
Gray matter, white matter —
separation by tissue properties
Cerebral cortical structure segmentation
boundary volume calculation for each lobe
Internal brain structures —
brainstem, thalamus, hippocampus, pituitary segmentation
Precision diagnosis
powered by AI MRI auto-quantification
LOW data
3D measurement
AI analyzes MRI LOW data
and reconstructs it into high-quality, precise 3D
medical data through deep learning algorithms
Density-Texture Analysis
Volumetric Quantification
Automated Segmentation
Intelligent
brain analysis reports,
AI insights
Machine learning algorithms predict
brain health, cognitive changes, and disease risk,
and automatically generate customized medical reports
with objective brain health insights for clinicians.
Intelligent
brain analysis reports,
AI insights
Machine learning algorithms predict
brain health, cognitive changes, and disease risk,
and automatically generate customized medical reports
with objective brain health insights for clinicians.
KFDA, FDA, CDSCO approvals
collaborating with world-leading hospitals
Proven technology with
domestic and international approvals
Specific-function approvals completed
in Korea, the U.S., and India;
full-function approvals in progress
In clinical pilot
at world-leading hospitals
Biomarkers from T1, T2, Diffusion, FLAIR, SWI, and fMRI
are being piloted at U.S. academic hospitals as evidence for accelerated MRI techniques
and protocol validation,
with models being retrained on U.S. patient data
KFDA, FDA, CDSCO approvals
collaborating with world-leading hospitals
Proven technology with
domestic and international approvals
Specific-function approvals completed
in Korea, the U.S., and India;
full-function approvals in progress
In clinical pilot
at world-leading hospitals
Biomarkers from T1, T2, Diffusion, FLAIR, SWI, and fMRI
are being piloted at U.S. academic hospitals as evidence for accelerated MRI techniques
and protocol validation,
with models being retrained on U.S. patient data